|
1. Scope and purpose
|
1
|
The overall objective(s) of the guideline is (are) specifically described
|
The overall objective(s) of the guideline is (are) specifically described
|
1
|
1. Scope and purpose
|
No change
|
|
2
|
The clinical question(s) covered by the guideline is (are) specifically described
|
The health question(s) covered by the guideline is (are) specifically described
|
2
|
Change in underline part
|
|
3
|
The patients to whom the guideline is meant to apply are specifically described
|
The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described
|
3
|
Change in underline part
|
|
2. Stakeholder involvement
|
4
|
The guideline development group includes individuals from all the relevant professional groups
|
The guideline development group includes individuals from all the relevant professional groups
|
4
|
2. Stakeholder involvement
|
No change
|
|
5
|
The patients’ views and preferences have been sought
|
The views and preferences of the target population (patients, public, etc.) have been sought
|
5
|
Change in underline part
|
|
6
|
The target users of the guideline are clearly defined. No
|
The target users of the guideline are clearly defined. No
|
6
|
No change
|
|
7
|
The guideline has been piloted among end users
| | | |
Delete item. Incorporated into user guide description of item 19
|
|
3. Rigour of development
|
8
|
Systematic methods were used to search for evidence
|
Systematic methods were used to search for evidence
|
7
|
3. Rigour of development
|
No change, renumber to 7
|
|
9
|
The criteria for selecting the evidence are clearly described
|
The criteria for selecting the evidence are clearly described
|
8
|
No change, renumber to 8
|
| | |
The strengths and limitations of the body of evidence are clearly described
|
9
|
New item
|
|
10
|
The methods for formulating the recommendations are clearly described
|
The methods for formulating the recommendations are clearly described
|
10
|
No change
|
|
11
|
The health benefits, side effects, and risks have been considered in formulating the recommendations
|
The health benefits, side effects, and risks have been considered in formulating the recommendations
|
11
|
No change
|
|
12
|
There is an explicit link between the recommendations and the supporting evidence
|
There is an explicit link between the recommendations and the supporting evidence
|
12
|
No change
|
|
13
|
The guideline has been externally reviewed by experts prior to its publication
|
The guideline has been externally reviewed by experts prior to its publication
|
13
|
No change
|
|
14
|
A procedure for updating the guideline is provided
|
A procedure for updating the guideline is provided
|
14
|
No change
|
|
4. Clarity of presentation
|
15
|
The recommendations are specific and unambiguous
|
The recommendations are specific and unambiguous
|
15
|
4. Clarity of presentation
|
No change
|
|
16
|
The different options for management of the condition are clearly presented
|
The different options for management of the condition or health issue are clearly presented
|
16
|
Change in underline part
|
|
17
|
Key recommendations are easily identifiable
|
Key recommendations are easily identifiable
|
17
|
No change
|
|
18
|
The guideline is supported with tools for application
|
The guideline describes facilitators and barriers to its application
|
19
|
5. Applicability
|
Change in underline part, renumber to 19, change in domain from #4 clarity of presentation to #5 applicability
|
|
5. Applicability
|
19
|
The potential organizational barriers in applying the recommendations have been discussed
|
The guideline provides advice and/or tools on how the recommendations can be put into practice
|
18
|
Change in underline part, renumber to 18.
|
|
20
|
The potential cost implications of applying the recommendations have been considered
|
The potential resource implications of applying the recommendations have been considered
|
20
|
Change in underline part
|
|
21
|
The guideline presents key review criteria for monitoring and/ or audit purposes
|
The guideline presents monitoring and/ or auditing criteria
|
21
|
Change in underline part
|
|
6. Editorial independence
|
22
|
The guideline is editorially independent from the funding body
|
The views of the funding body have not influenced the content of the guideline
|
22
|
6. Editorial independence
|
Change in underline part
|
|
23
|
Conflicts of interest of guideline development members have been recorded
|
Competing interests of guideline development group members have been recorded and addressed
|
23
|
Change in underline part
|
|
Overall guideline assessment
| | |
Rate the overall quality of this guideline
|
1
|
Overall guideline assessment
|
New item
|
|
1
|
I would recommend this guideline for use
|
I would recommend this guideline for use
|
2
|
Renumber to 2
|
